"Smoking Cessation Drugs Market Will Reach $2.4 Billion in 2012" Visiongain Report Predicts
A new report by visiongain predicts that the world market for smoking cessation medicines will reach $2.4 billion for 2012.
London, United Kingdom, April 16, 2012 --(PR.com)-- That revenue forecast appears in Smoking Cessation Drugs: World Market Prospects 2012-2022, published in April 2012. Visiongain is a business information provider based in London, UK.
Visiongain’s study predicts that the smoking cessation drug market will grow during the forecast period 2012 to 2022. Rising incidence and prevalence of smoking will stimulate revenue growth, especially in developing countries. The scope of the market is broadening, with millions of smokers wanting to stop smoking.
From 2012 to 2022, the pharmaceutical industry will improve treatments to stop smoking. The R&D pipeline is promising. New formulations and generics will be important too. Innovations in drug delivery and rising demand in developing countries will also stimulate the industry and market.
Kritika Chaudhari, a pharmaceutical industry analyst at visiongain, said: “In general, smoking cessation drugs suffer from two drawbacks at present. First, they have notable side effects. Second, is the challenge of smokers relapsing after treatment with anti-smoking medication. These difficulties are being recognised; addressing them will benefit the smoking cessation drugs market from 2012 to 2022.”
Visiongain’s report provides revenue forecasts to 2022 at world market, submarket, product and national level. It forecasts world sales for the following submarkets:
• Over-the-counter (OTC) smoking cessation products
• Prescription (Rx) drugs
• Nicotine replacement therapy (NRT)
• Nicotine receptor partial agonists
• Antidepressant therapy segment.
That investigation forecasts sales of leading drugs in the smoking treatments market, including Nicorette, Nicotinell and Champix/Chantix. Research, data and analyses cover activities of Pfizer, GSK, Novartis and other pharmaceutical companies.
The analysis includes researching the R&D pipeline, interviewing authorities on the industry and forecasting revenues in leading national markets. Countries analysed are the US, Japan, the EU5, China and India. Smoking Cessation Drugs: World Market Prospects 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For sample pages and further information concerning the visiongain report Smoking Cessation Drugs: World Market Prospects 2012-2022 please visit: http://www.visiongain.com/Report/800/Smoking-Cessation-Drugs-World-Market-Prospects-2012-2022
For an executive summary of this report or to order it today please email:
Sara Peerun at sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent business intelligence companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters and management reports focusing on the Energy, Telecoms, Pharmaceuticals, Defence, Aviation and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Visiongain’s study predicts that the smoking cessation drug market will grow during the forecast period 2012 to 2022. Rising incidence and prevalence of smoking will stimulate revenue growth, especially in developing countries. The scope of the market is broadening, with millions of smokers wanting to stop smoking.
From 2012 to 2022, the pharmaceutical industry will improve treatments to stop smoking. The R&D pipeline is promising. New formulations and generics will be important too. Innovations in drug delivery and rising demand in developing countries will also stimulate the industry and market.
Kritika Chaudhari, a pharmaceutical industry analyst at visiongain, said: “In general, smoking cessation drugs suffer from two drawbacks at present. First, they have notable side effects. Second, is the challenge of smokers relapsing after treatment with anti-smoking medication. These difficulties are being recognised; addressing them will benefit the smoking cessation drugs market from 2012 to 2022.”
Visiongain’s report provides revenue forecasts to 2022 at world market, submarket, product and national level. It forecasts world sales for the following submarkets:
• Over-the-counter (OTC) smoking cessation products
• Prescription (Rx) drugs
• Nicotine replacement therapy (NRT)
• Nicotine receptor partial agonists
• Antidepressant therapy segment.
That investigation forecasts sales of leading drugs in the smoking treatments market, including Nicorette, Nicotinell and Champix/Chantix. Research, data and analyses cover activities of Pfizer, GSK, Novartis and other pharmaceutical companies.
The analysis includes researching the R&D pipeline, interviewing authorities on the industry and forecasting revenues in leading national markets. Countries analysed are the US, Japan, the EU5, China and India. Smoking Cessation Drugs: World Market Prospects 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For sample pages and further information concerning the visiongain report Smoking Cessation Drugs: World Market Prospects 2012-2022 please visit: http://www.visiongain.com/Report/800/Smoking-Cessation-Drugs-World-Market-Prospects-2012-2022
For an executive summary of this report or to order it today please email:
Sara Peerun at sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100
About visiongain
Visiongain is one of the fastest growing and most innovative independent business intelligence companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters and management reports focusing on the Energy, Telecoms, Pharmaceuticals, Defence, Aviation and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
Contact
Visiongain
Sara Peerun
+44 020 7336 6100
www.visiongain.com
Sara Peerun
+44 020 7336 6100
www.visiongain.com
Contact
Categories